氯倍他索丁酸酯 | 25122-47-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 氯倍他索丁酸酯
• 英文名称: clobetasol-17-butyrate
• 英文别名: 21-Chlor-betamethason-17-butyrat；clobetasone 17-butyrate；clobetasol butyrate；clobetasone butyrate；clobetasol 17-propionate；Clobetasol 17-butyrate；[(8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] butanoate
• CAS: 25122-47-8
• 化学式: C₂₆H₃₄ClFO₅
• 分子量: 481.004
• InChiKey: DERCOWNWEPPIHD-SOMXGXJRSA-N

物化性质

• 沸点：
  579.1±50.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  80.7
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  (4R,8'S,9'R,10'S,11'S,13'S,14'S,16'S)-9'-fluoro-11'-hydroxy-2-methoxy-10',13',16'-trimethyl-2-propylspiro[1,3-dioxane-4,17'-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene]-3',5-dione 在 三甲基氯硅烷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 氯倍他索丁酸酯
  参考文献：
  名称：

  CH609709

  摘要：

  公开号：

文献信息

• METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT
  申请人：Stover Richard R.

  公开号：US20080175891A1

  公开（公告）日：2008-07-24

  The present invention provides transdermal administration of AICA riboside, or a prodrugs, analogs, or salts thereof, and/or a blood clotting inhibitor for preventing or reducing adverse side effects in a patient. The type of patient that may benefit includes a patient with decreased left ventricular function, a patient with a prior myocardial infarction, a patient undergoing non-vascular surgery, or a fetus during labor and delivery.

  本发明提供了通过经皮途径给予AICA核糖苷，或其前药、类似物或盐，和/或血液凝块抑制剂以预防或减少患者的不良副作用。可能受益的患者类型包括左心室功能减退的患者、先前发生心肌梗死的患者、接受非血管手术的患者，或分娩期间的胎儿。
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT D'UNE INFLAMMATION
  申请人：RESOLVYX PHARMACEUTICALS INC

  公开号：WO2010120719A1

  公开（公告）日：2010-10-21

  The invention relates to novel resolvin compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel resolvin compounds of the invention.

  这项发明涉及新型利用新型resolvin化合物和其药物制剂的治疗方法。
• [EN] IMIDAZOLOPYRIMIDIN-2-YL DERIVATIVES AS JAK INHIBITORS<br/>[FR] DÉRIVÉS D'IMIDAZOPYRIDMIN-2-YL COMME INHIBITEURS DE LA JAK
  申请人：ALMIRALL SA

  公开号：WO2015091531A1

  公开（公告）日：2015-06-25

  New imidazopyridmin-2-yl derivatives are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use as inhibitors of Janus Kinases (JAK) for the treatment of myeloproliferative disorders, leukemia, lymphoid malignancies and solid tumors; bone marrow and organ transplant rejection; immune-mediated diseases and inflammatory diseases.

  新的咪唑吡啶-2-基衍生物已被披露；以及它们的制备方法，包含它们的药物组合物以及它们作为Janus激酶（JAK）抑制剂用于治疗骨髓增生性疾病、白血病、淋巴瘤恶性肿瘤、骨髓和器官移植排斥反应、免疫介导性疾病和炎症性疾病的用途。
• CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION
  申请人：Manoharan Muthiah

  公开号：US20120035115A1

  公开（公告）日：2012-02-09

  The invention features compounds of formula I or II: In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression.

  该发明涉及公式I或II的化合物：在一种实施方式中，该发明涉及化合物和用于将配体与寡核苷酸结合的过程。该发明进一步涉及治疗各种疾病和疾病的方法，例如病毒感染、细菌感染、寄生虫感染、癌症、过敏、自身免疫疾病、免疫缺陷和免疫抑制。
• [EN] THERAPEUTIC COMPOUNDS<br/>[FR] COMPOSÉS THÉRAPEUTIQUES
  申请人：RESOLVYX PHARMACEUTICALS INC

  公开号：WO2010039531A1

  公开（公告）日：2010-04-08

  The invention relates to novel resolvin compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel resolvin compounds of the invention.

  这项发明涉及新型resolvin化合物及其制药制剂。该发明还涉及使用该发明的新型resolvin化合物进行治疗的方法。